1. Home
  2. JCE vs NYXH Comparison

JCE vs NYXH Comparison

Compare JCE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JCE
  • NYXH
  • Stock Information
  • Founded
  • JCE 2007
  • NYXH 2009
  • Country
  • JCE United States
  • NYXH Belgium
  • Employees
  • JCE N/A
  • NYXH N/A
  • Industry
  • JCE Trusts Except Educational Religious and Charitable
  • NYXH Medical/Dental Instruments
  • Sector
  • JCE Finance
  • NYXH Health Care
  • Exchange
  • JCE Nasdaq
  • NYXH Nasdaq
  • Market Cap
  • JCE 249.7M
  • NYXH 261.1M
  • IPO Year
  • JCE N/A
  • NYXH 2021
  • Fundamental
  • Price
  • JCE $15.28
  • NYXH $8.22
  • Analyst Decision
  • JCE
  • NYXH Strong Buy
  • Analyst Count
  • JCE 0
  • NYXH 5
  • Target Price
  • JCE N/A
  • NYXH $17.00
  • AVG Volume (30 Days)
  • JCE 49.7K
  • NYXH 26.6K
  • Earning Date
  • JCE 01-01-0001
  • NYXH 11-06-2024
  • Dividend Yield
  • JCE 9.26%
  • NYXH N/A
  • EPS Growth
  • JCE N/A
  • NYXH N/A
  • EPS
  • JCE N/A
  • NYXH N/A
  • Revenue
  • JCE N/A
  • NYXH $5,668,079.00
  • Revenue This Year
  • JCE N/A
  • NYXH $37.10
  • Revenue Next Year
  • JCE N/A
  • NYXH $418.12
  • P/E Ratio
  • JCE N/A
  • NYXH N/A
  • Revenue Growth
  • JCE N/A
  • NYXH 32.65
  • 52 Week Low
  • JCE $11.64
  • NYXH $4.00
  • 52 Week High
  • JCE $14.28
  • NYXH $20.00
  • Technical
  • Relative Strength Index (RSI)
  • JCE 48.94
  • NYXH 30.23
  • Support Level
  • JCE $14.94
  • NYXH $8.10
  • Resistance Level
  • JCE $15.65
  • NYXH $10.01
  • Average True Range (ATR)
  • JCE 0.24
  • NYXH 0.47
  • MACD
  • JCE 0.02
  • NYXH -0.19
  • Stochastic Oscillator
  • JCE 53.16
  • NYXH 6.28

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities (the Options Strategy).

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: